These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

896 related articles for article (PubMed ID: 28508916)

  • 1. Direct oral anticoagulants for the treatment of cancer-associated venous thromboembolism. What do we know so far?
    Voigtlaender M; Langer F
    Hamostaseologie; 2017 Oct; 37(4):241-255. PubMed ID: 28508916
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Analysis of the Risk Factors Associated with Minor Bleeding in Patients with Venous Thromboembolism during Treatment with Direct Oral Anticoagulants].
    Sunaga T; Shimizu T; Nakamura S; Takahashi N; Higashino M; Matsui M; Hozumi T; Ebato M; Suzuki H; Kogo M; Watanabe T; Sasaki T
    Yakugaku Zasshi; 2019; 139(3):461-467. PubMed ID: 30828024
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Direct oral anticoagulants in the treatment of acute venous thromboembolism: a systematic review and meta-analysis.
    Gómez-Outes A; Terleira-Fernández AI; Lecumberri R; Suárez-Gea ML; Vargas-Castrillón E
    Thromb Res; 2014 Oct; 134(4):774-82. PubMed ID: 25037495
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of the Novel Oral Anticoagulants Apixaban, Dabigatran, Edoxaban, and Rivaroxaban in the Initial and Long-Term Treatment and Prevention of Venous Thromboembolism: Systematic Review and Network Meta-Analysis.
    Cohen AT; Hamilton M; Mitchell SA; Phatak H; Liu X; Bird A; Tushabe D; Batson S
    PLoS One; 2015; 10(12):e0144856. PubMed ID: 26716830
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Direct oral anticoagulants for the treatment of cancer-associated venous thromboembolism.
    Voigtlaender M; Langer F
    Hamostaseologie; 2017; 37(4):241-255. PubMed ID: 29582927
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of the Non-VKA Oral Anticoagulants Apixaban, Dabigatran, and Rivaroxaban in the Extended Treatment and Prevention of Venous Thromboembolism: Systematic Review and Network Meta-Analysis.
    Cohen AT; Hamilton M; Bird A; Mitchell SA; Li S; Horblyuk R; Batson S
    PLoS One; 2016; 11(8):e0160064. PubMed ID: 27487187
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Optimizing the safety of treatment for venous thromboembolism in the era of direct oral anticoagulants.
    Weitz JI; Jaffer IH
    Pol Arch Med Wewn; 2016 Sep; 126(9):688-696. PubMed ID: 27592622
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Editor's Choice - efficacy and safety of the new oral anticoagulants dabigatran, rivaroxaban, apixaban, and edoxaban in the treatment and secondary prevention of venous thromboembolism: a systematic review and meta-analysis of phase III trials.
    Kakkos SK; Kirkilesis GI; Tsolakis IA
    Eur J Vasc Endovasc Surg; 2014 Nov; 48(5):565-75. PubMed ID: 24951377
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase III trials of new oral anticoagulants in the acute treatment and secondary prevention of VTE: comparison and critique of study methodology and results.
    Cohen AT; Imfeld S; Rider T
    Adv Ther; 2014 May; 31(5):473-93. PubMed ID: 24821599
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Management of Venous Thromboembolism: Recent Advances in Oral Anticoagulation Therapy.
    Finks SW; Trujillo TC; Dobesh PP
    Ann Pharmacother; 2016 Jun; 50(6):486-501. PubMed ID: 26917821
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Direct oral anticoagulants compared with vitamin K antagonists for acute venous thromboembolism: evidence from phase 3 trials.
    van Es N; Coppens M; Schulman S; Middeldorp S; Büller HR
    Blood; 2014 Sep; 124(12):1968-75. PubMed ID: 24963045
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Relative efficacy and safety of non-Vitamin K oral anticoagulants for non-valvular atrial fibrillation: Network meta-analysis comparing apixaban, dabigatran, rivaroxaban and edoxaban in three patient subgroups.
    Lip GY; Mitchell SA; Liu X; Liu LZ; Phatak H; Kachroo S; Batson S
    Int J Cardiol; 2016 Feb; 204():88-94. PubMed ID: 26655548
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Update on Direct Oral AntiCoagulants (DOACs).
    Koscielny J; Rosenthal C; von Heymann C
    Hamostaseologie; 2017; 37(4):267-275. PubMed ID: 29582929
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Extended treatment with non-vitamin K antagonist oral anticoagulants versus low-molecular-weight heparins in cancer patients following venous thromboembolism. A pilot study.
    Stepien K; Nowak K; Zalewski J; Pac A; Undas A
    Vascul Pharmacol; 2019 Sep; 120():106567. PubMed ID: 31158568
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Peculiarities of the treatment of venous thromboembolism with direct oral anticoagulants in challenging patients: senile age, renal failure, fragility].
    Schastlivtsev IV; Lobastov KV
    Khirurgiia (Mosk); 2020; (7):68-75. PubMed ID: 32736466
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of Direct-Acting Oral Anticoagulant Use in Patients With Cancer.
    Davis DO; Davis KA
    J Pharm Pract; 2018 Oct; 31(5):441-444. PubMed ID: 28803521
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sex related differences in patients with acute venous thromboembolism treated with new oral anticoagulants. A meta-analysis of the interventional trials.
    Loffredo L; Violi F; Perri L
    Int J Cardiol; 2016 Jun; 212():255-8. PubMed ID: 27057930
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical experience with the new oral anticoagulants for treatment of venous thromboembolism.
    Bacchus F; Schulman S
    Arterioscler Thromb Vasc Biol; 2015 Mar; 35(3):513-9. PubMed ID: 25717178
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pros and cons of new oral anticoagulants in the treatment of venous thromboembolism in patients with cancer.
    Verso M; Agnelli G; Prandoni P
    Intern Emerg Med; 2015 Sep; 10(6):651-6. PubMed ID: 25840679
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effectiveness and Safety of Direct Oral Anticoagulants versus Warfarin in Obese Patients with Acute Venous Thromboembolism.
    Coons JC; Albert L; Bejjani A; Iasella CJ
    Pharmacotherapy; 2020 Mar; 40(3):204-210. PubMed ID: 31968126
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 45.